Alexander J. Denner - Dec 15, 2023 Form 4 Insider Report for IRONWOOD PHARMACEUTICALS INC (IRWD)

Role
Director, 10%+ Owner
Signature
SARISSA CAPITAL MANAGEMENT LP, By: /s/ Mark DiPaolo, Name: Mark DiPaolo, Title: Senior Partner, General Counsel
Stock symbol
IRWD
Transactions as of
Dec 15, 2023
Transactions value $
$0
Form type
4
Date filed
12/19/2023, 04:05 PM
Previous filing
Sep 19, 2023
Next filing
Mar 19, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IRWD Class A Common Stock Award $0 +1.35K +1.13% $0.00 120K Dec 15, 2023 Direct F1
holding IRWD Class A Common Stock 16.4M Dec 15, 2023 See footnote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Issued pursuant to the Amended and Restated Non-employee Director Compensation Policy, effective January 1, 2023.
F2 Consists of shares that are held by Sarissa Capital Management LP ("Sarissa Capital") or by the funds and other investment vehicles (the "Sarissa Funds") for which Sarissa Capital serves as investment advisor. Dr. Denner is the Chief Investment Officer of Sarissa Capital and the managing member, general partner or other control party of the Sarissa Funds. By virtue of the foregoing, Dr. Denner may be deemed to indirectly beneficially own the shares that these funds directly beneficially own. Each of Sarissa Capital, the Sarissa Funds and Dr. Denner disclaims beneficial ownership of these shares except, in each case, to the extent of their pecuniary interest therein.

Remarks:

Exhibit 24 - Limited Power of Attorney